(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 November 2006 (23.11.2006)

PCT

(10) International Publication Number
WO 2006/122661 A1

(51) International Patent Classification:
C07D 409/12 (2006.01) *C07D 211/58* (2006.01)
A61K 31/4535 (2006.01) *C07D 401/12* (2006.01)
A61P 7/02 (2006.01) *C07D 413/14* (2006.01)
C07D 409/14 (2006.01) *C07D 417/14* (2006.01)
C07D 333/38 (2006.01) *C07D 419/14* (2006.01)
C07D 405/12 (2006.01)

(21) International Application Number:
PCT/EP2006/004255

(22) International Filing Date: 6 May 2006 (06.05.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05010929.7 20 May 2005 (20.05.2005) EP

(71) Applicant *(for all designated States except US)*: **SANOFI-AVENTIS DEUTSCHLAND GMBH** [DE/DE]; Brüningstrasse 50, 65929 Frankfurt am Main (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **WAGNER, Michael** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **URMANN, Matthias** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **WEHNER, Volkmar** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **LORENZ, Martin** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **BAUER, Armin** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **NAZARÉ, Marc** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE). **MATTER, Hans** [DE/DE]; c/o Sanofi Aventis Deutschland GmbH, 65926 Frankfurt am Main (DE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) **Title:** HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS



(I)

(57) **Abstract:** The present invention relates to compounds of the Formula (I), in which R1; R2; R3; V; G1 and G2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa, and can in general be applied in conditions in which an undesired activity of factor Xa is present or for the cure or prevention of which an inhibition of factor Xa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

WO 2006/122661 A1